



**Clinical Research Trials**

**Principal Investigators Include: Stephen Khachikian, MD**

**Terrence Spencer, MD & Adam Jorgensen, MD**

For more information please call Kayla Riley at 605-341-9190 or 605-390-9437

Company & Study name	Study Rationale	Current Enrollment
<b>Upcoming</b>		
<b>Dry Eye Trial</b> PI: Spencer SUBI: Khachikian	A Phase 3, Double Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle In Subjects With Dry Eye Disease (STRIDE 3)	<b>Open</b>
<b>Dry Eye Trial</b> PI: Khachikian SUB: Spencer	A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of SJP-0035 0.001% for the Treatment of Patients with Dry Eye Disease (DELTA-1 Study)	<b>Open</b>
<b>Glaucoma Trial</b> PI:Jorgensen SUBI: Spencer & Khachikian	A Phase III, Randomized Double-Masked, Active-Controlled, Parallel-Group, Multi-center Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution 0.002% Compared with Timolol Maleate Ophthalmic Solution 0.5% in Subjects with Glaucoma or Ocular Hypertension – Spectrum 3 Study	<b>Open</b>
<b>SHP640301 &amp; 303 Conjunctivitis</b>	A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis	<b>Open</b>
<b>LOS-001 Sjogren's Dry Eye</b>	A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Dosed of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration. Patients with Sjogren's Only	<b>Open</b>
<b>Cataract Trial</b> PI; Khachikian SUBI: Spencer & Jorgensen	A Phase ½ Dose-Ranging, Open-Label, Randomized, Clinical Study to Assess the Efficacy and Safety of SED80 for the treatment of inflammation Associated with Cataract Surgery	<b>Upcoming</b>
<b>Cataract Trial</b> PI: Spencer SUBI: Khachikian & Jorgensen	A Phase 3, Randomized, Multicenter, Double-Masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (031% Dexamethasone in DuarSite 2) to SuraSite 2 Vehicle for the treatment of Inflammation and Pain Associated with Cataract Surgery.	<b>Upcoming</b>
<b>Contact Kayla Riley at 605-719-3153 or 605-390-9437</b>		